Castle Biosciences (CSTL) Cost of Revenue (2018 - 2026)

Castle Biosciences has disclosed Cost of Revenue across 9 years of filings, most recently posting $20.5 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $20.5 million, up 25.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $75.2 million (up 19.91% YoY), and the FY2025 annual result was $71.0 million, up 17.98% from the prior year.
• Cost of Revenue came in at $20.5 million for Q1 2026 at Castle Biosciences, up from $18.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $20.5 million in Q1 2026 to a low of $5.9 million in Q1 2022.
• The 5-year median for Cost of Revenue is $13.9 million (2024), against an average of $13.5 million.
• Across the five-year window, Cost of Revenue surged 107.9% in 2022 and grew 13.17% in 2025, its largest moves.
• Castle Biosciences' Cost of Revenue stood at $9.5 million in 2022, then surged by 30.49% to $12.4 million in 2023, then jumped by 30.27% to $16.2 million in 2024, then gained by 13.17% to $18.3 million in 2025, then gained by 12.11% to $20.5 million in 2026.
• The last three Cost of Revenue figures came in at $20.5 million (Q1 2026), $18.3 million (Q4 2025), and $18.7 million (Q3 2025), per Business Quant data.